Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hydroxylysine kinase (HYKK) is an enzyme (EC 2.7.1.81) that catalyzes the phosphorylation of 5-hydroxy-L-lysine using GTP as a phosphate donor, forming GDP and 5-phosphonooxy-L-lysine[2][3]. It is encoded by the HYKK/AGPHD1 gene in humans[3][4]. This enzyme participates in the catabolism of hydroxylysine, a modified amino acid generated during collagen breakdown, and primarily functions in liver and kidney[3]. Deficiencies in hydroxylysine kinase are linked to rare inherited metabolic disorders such as hydroxylysinuria and hydroxylysinemia, with some patients displaying neurological symptoms, though disease causality remains under study[3]. Currently, hydroxylysine kinase is not a direct drug target and has no established interacting small molecules, but it is important in amino acid and connective tissue metabolism[2][3][4].
Catalyzes the GTP-dependent phosphorylation of 5-hydroxy-L-lysine, forming 5-phosphonooxy-L-lysine[2][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hydroxylysine kinase (HYKK).